Neurological Therapeutics
Online ISSN : 2189-7824
Print ISSN : 0916-8443
ISSN-L : 2189-7824
 
Neurological disease treatment in the age of COVID–19
Shigeki Yamaguchi
Author information
JOURNAL FREE ACCESS

2022 Volume 39 Issue 3 Pages 224-228

Details
Abstract

We reviewed the current status of neuromuscular diseases in the COVID–19 epidemic and the nursing system for patients with cognitive decline and delirium who are hospitalized with COVID–19. COVID–19–related neurological diseases range from non–specific symptoms such as headache and fatigue to specific symptoms such as olfactory and gustatory disorders, autoimmune diseases, and stroke. The frequency of neurological complications of COVID–19 is higher than that of other viral diseases such as influenza, and the severity is particularly high in severe cases and patients with dementia. In patients with dementia, infection and serious illnesses are more frequent due to lack of understanding of infection prevention measures, and cognitive function may deteriorate due to isolation in nursing care. We believe that it will be important to take a new perspective in response to social structural changes, such as the use of IT equipment and the telemedicine.

Content from these authors
© 2022 Japanese Society of Neurological Therapeutics
Previous article Next article
feedback
Top